Phase 1 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and sign a consent form
• People aged between 18 and 75 years old (any gender)
• People diagnosed with acute myeloid leukaemia (AML) that has come back or has not responded to standard treatment — this includes a range of specific situations such as the cancer not going into remission after two rounds of standard treatment, the cancer returning after previous treatment, or the cancer being present in areas outside the bone marrow (confirm specific situation with trial site)
• People whose doctors expect them to survive for at least 12 weeks
• People whose leukaemia cells show a certain protein marker called LILRA6 on at least 20% of the cancer cells, as measured by a lab test
• People with a reasonable level of general physical functioning, as rated on a standard medical scale (ECOG score of 0–2, meaning able to carry out normal daily activities with little to no limitation)
• People whose liver, kidneys, heart, lungs, and blood counts meet certain minimum levels of healthy function, as confirmed by blood and other tests
• People who have previously had one autologous stem cell transplant (a transplant using their own stem cells) may be eligible
• Women of childbearing age whose pregnancy test comes back negative, and who agree to use effective contraception throughout the trial
• People who do not have any uncontrolled infections, including lung infections, at the time of joining
• People who have finished their last cancer treatment at least 3 weeks ago (for chemotherapy, radiation, or immunotherapy) or at least 2 weeks ago (for targeted drugs)
• People who do not currently have an active COVID-19 or influenza infection

Who may not be able to join:

• People who have had a serious allergic reaction to any ingredient in the cell treatment or the pre-treatment chemotherapy drugs used in this trial
• People who have or have had another active cancer diagnosis
• People who have an active infection currently requiring treatment — though people taking preventive antibiotics, antiviral, or antifungal medication may still be considered
• People with active hepatitis B (at certain viral levels), hepatitis C, syphilis, HIV, or other immune deficiency conditions
• People with significant heart failure, classified as Grade III or IV by standard heart function guidelines
• People who still have side effects from previous cancer treatment that remain above a mild level (with the exception of tiredness, loss of appetite, or hair loss)
• People with a history of epilepsy or other neurological conditions that could affect how trial results are assessed
• People who have previously received any treatment that specifically targets the LILRA6 protein
• Women who are breastfeeding and do not wish to stop during the trial
• People whom the trial doctors consider to have other circumstances that could increase their risk or affect the trial results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.